STOCK TITAN

Linda Llewelyn files to sell 8,519 restricted shares (HCAT)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Health Catalyst, Inc. proposed the sale of 8,519 shares of Restricted Stock on 06/01/2026 under a Form 144 notice. The filing shows these shares are linked to compensation. The filing also reports 13,836 shares sold on 03/02/2026 by Linda Llewelyn, with proceeds noted as $22,966.38.

Positive

  • None.

Negative

  • None.

Insights

Proposed sale of 8,519 restricted shares by an insider; prior sale of 13,836 shares was reported.

The notice lists 8,519 shares of Restricted Stock proposed for sale on 06/01/2026, described as tied to compensation. The filer also reported a prior disposition of 13,836 shares on 03/02/2026 with proceeds shown as $22,966.38.

These are administrative disclosures of an insider sale plan; cash-flow treatment and any trading method are not provided in the excerpt. Subsequent filings would show completion or settlement details.

Proposed shares to be sold 8,519 shares Securities to be sold on 06/01/2026
Shares sold in past 3 months 13,836 shares Disposition dated 03/02/2026
Proceeds reported $22,966.38 Amount associated with prior 03/02/2026 disposition
Restricted Stock financial
"Securities To Be Sold ... Restricted Stock ... Compensation"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
Form 144 regulatory
"Filer Information | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Compensation financial
"Securities To Be Sold ... Compensation"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does Health Catalyst's (HCAT) Form 144 disclose?

The Form 144 discloses a proposed sale of 8,519 restricted shares on 06/01/2026. It also reports a prior disposition of 13,836 shares on 03/02/2026, tied to compensation, with proceeds listed as $22,966.38.

Who is the filer on the HCAT Form 144 and what security is affected?

The filing lists Linda Llewelyn as the reporting person and identifies Restricted Stock of Health Catalyst, Inc. The notice reports shares related to compensation and specifies the proposed sale date as 06/01/2026 in the excerpt.

How many shares were sold in the prior transaction reported in the Form 144?

The excerpt shows a prior sale of 13,836 shares on 03/02/2026. The filing ties that prior disposition to restricted stock activity and includes proceeds recorded as $22,966.38 in the provided lines.

Does the Form 144 indicate how proceeds will be used or who receives them?

The excerpt does not specify use of proceeds or the recipient beyond the reporting person. It lists proceeds of $22,966.38 for the prior sale, but the filing does not describe cash-flow treatment or disposition method in the provided content.